Aciont Inc. endeavors to become the world leader in commercializing localized, non-invasive and controlled release back of the eye therapeutics for sight threatening diseases. Iontophoresis is the basis for the company's Visulex transcleral ocular drug delivery system, which endeavors to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye diseases through optimal drug dosing and improved patient/physician compliance. Aciont is located in Salt Lake City, Utah.